OpGen to Provide Business Update and Financial Results for the Third Quarter 2020
OpGen, Inc. (NASDAQ: OPGN) will release its third quarter 2020 financial results and provide a business update on November 11, 2020, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OpGen, Inc. (NASDAQ: OPGN) will release its third quarter 2020 financial results and provide a business update on November 11, 2020, after U.S. market close. The management team will host a live call at 4:30 p.m. ET to discuss the results. Investors can join via U.S. dial-in at +1 (877) 705 6003 or international dial-in at +1 (201) 493 6725. A replay will be available until November 25, 2020. OpGen focuses on molecular diagnostics for infectious diseases, aiming to improve patient outcomes by addressing multidrug-resistant organisms.
Positive
- Scheduled earnings call on November 11, 2020, may provide positive updates.
- Focus on molecular diagnostics positions the company for future growth.
Negative
- None.
Details
News Market Reaction – OPGN
The recorded move for OPGN in the trading session of this news was -1.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 11, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
| Conference Call Details | ||
| U.S. Dial-in Number: | +1 (877) 705 6003 | |
| International Dial-in Number: | +1 (201) 493 6725 | |
| Webcast: | http://public.viavid.com/index.php?id=142176 | |
| Conference ID: | 13712431 | |
| Replay Details | ||
| U.S. Dial-in Number: | +1 (844) 512 2921 | |
| International Dial-in Number: | +1 (412) 317 6671 | |
| Replay PIN: | 13712431 | |
Following the conclusion of the conference call, a replay will be available through November 25, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com
OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:
Megan Paul
Edison Group
mpaul@edisongroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.